| Year |
Title |
Altmetric |
| 2023
|
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.
JCO Clinical Cancer Informatics.
7:e2200103.
2023
|
|
| 2022
|
Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN.
20:973-980.
2022
|
|
| 2022
|
The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
Gynecologic Oncology.
166:417-424.
2022
|
|
| 2022
|
Barriers and facilitators affecting presentation in women with early versus advanced stage cervical cancer.
Gynecologic Oncology Reports.
40.
2022
|
|
| 2022
|
Cervical cancer – times… they are a changing: A report from the Society of Gynecologic Oncology journal club.
Gynecologic Oncology Reports.
40.
2022
|
|
| 2022
|
Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications.
Current Oncology Reports.
24:389-397.
2022
|
|
| 2022
|
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: Interim results from GARNET - A phase I, single-arm study.
Journal for ImmunoTherapy of Cancer.
10.
2022
|
|
| 2022
|
Feasibility, Safety, and Provider Perspectives of Bipolar Electrosurgical Cautery Device for (Opportunistic or Complete) Salpingectomy at the Time of Cesarean Delivery.
American Journal of Perinatology.
2022
|
|
| 2022
|
Sociodemographic characteristics and cervical cancer survival in different regions of the United States: A National Cancer Database study.
International Journal of Gynecological Cancer.
2022
|
|
| 2022
|
Using an Environmentally Friendly Disposal Bag to Discard Leftover Opioids After Gynecologic Surgery.
Obstetrics and Gynecology.
139:91-96.
2022
|
|
| 2021
|
Gynecologic oncology patients are ready for telemedicine in routine care: Results from a pre-COVID survey.
Gynecologic Oncology Reports.
38.
2021
|
|
| 2021
|
Identifying a molecular profile to predict the risk of recurrence in high-intermediate risk endometrial cancer.
Cancer Medicine.
10:8238-8250.
2021
|
|
| 2021
|
GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.
Clinical Cancer Research.
27:5536-5545.
2021
|
|
| 2021
|
Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study.
Gynecologic Oncology.
163:85-92.
2021
|
|
| 2021
|
An enhanced recovery protocol decreases complication rates in high-risk gynecologic oncology patients undergoing non-emergent laparotomy.
International Journal of Gynecological Cancer.
31:647-655.
2021
|
|
| 2021
|
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
2021
|
|
| 2021
|
Ovarian cancer, version 2.2020.
Journal of the National Comprehensive Cancer Network : JNCCN.
19:191-226.
2021
|
|
| 2021
|
Fluorescence Imaging of the Ureter in Minimally Invasive Pelvic Surgery.
Journal of Minimally Invasive Gynecology.
28:332-341.e14.
2021
|
|
| 2020
|
A Multi-atlas Approach for Active Bone Marrow Sparing Radiation Therapy: Implementation in the NRG-GY006 Trial
2020
|
|
| 2020
|
Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm.
Gynecologic Oncology.
159:773-777.
2020
|
|
| 2020
|
Advances in immunotherapy for cervical cancer.
Current Opinion in Oncology.
32:481-487.
2020
|
|
| 2020
|
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
Gynecologic Oncology.
158:562-569.
2020
|
|
| 2020
|
Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer..
Clinical Practice and Cases in Emergency Medicine.
4:227-229.
2020
|
|
| 2020
|
Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): A randomized phase III trial.
Journal of Clinical Oncology.
38:1164-1174.
2020
|
|
| 2020
|
Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.
Drugs.
80:217-227.
2020
|
|
| 2020
|
The Reliability of Intraoperative Assessment on Predicting Tumor Size, Myometrial Invasion, and Cervical Involvement in Patients with a Preoperative Diagnosis of Complex Atypical Hyperplasia or (Clinical Stage I) Endometrial Cancer: A Prospective Cohort Study
2020
|
|
| 2019
|
Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer.
New England Journal of Medicine.
381:2403-2415.
2019
|
|
| 2019
|
Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.
Gynecologic Oncology.
155:365-373.
2019
|
|
| 2019
|
Neutrophilia and mortality in women with uterine carcinosarcoma.
International Journal of Gynecological Cancer.
29:1258-1263.
2019
|
|
| 2019
|
Assessing recurrence risk following intraperitoneal chemotherapy for ovarian cancer: A day late and a dollar short?.
Gynecologic Oncology Reports.
29:111-112.
2019
|
|
| 2019
|
Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
Gynecologic Oncology.
154:379-382.
2019
|
|
| 2019
|
Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting.
Gynecologic Oncology Reports.
29:123-125.
2019
|
|
| 2019
|
Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution.
Gynecologic Oncology.
153:242-247.
2019
|
|
| 2019
|
Options for assisted reproduction in young women with uterine cancer a cost-effectiveness analysis
2019
|
|
| 2019
|
Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients with Febrile Neutropenia
2019
|
|
| 2019
|
Response to “surgical management of cervical cancer by laparoscopy or laparotomy”.
Gynecologic Oncology Reports.
27:6-7.
2019
|
|
| 2019
|
Ovarian cancer, version 1.2019 featured updates to the nccn guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN.
17:896-909.
2019
|
|
| 2019
|
The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
Gynecologic Oncology.
152:127-132.
2019
|
|
| 2019
|
Utilization of an alternative docetaxel-based intraperitoneal chemotherapy regimen in patients with ovarian, fallopian tube or primary peritoneal carcinoma
2019
|
|
| 2018
|
Enhanced Recovery After Surgery in Surgical Specialties: Gynecologic Oncology.
Surgical Clinics of North America.
98:1275-1285.
2018
|
|
| 2018
|
Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy.
Gynecologic Oncology.
151:282-286.
2018
|
|
| 2018
|
The impact of racial, geographic, and socioeconomic risk factors on the development of advanced-stage cervical cancer.
Journal of Lower Genital Tract Disease.
22:269-273.
2018
|
|
| 2018
|
Predictors of Unplanned Reoperation for Ovarian Cancer Patients from the National Surgical Quality Improvement Program Database.
International Journal of Gynecological Cancer.
28:1427-1431.
2018
|
|
| 2018
|
Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.
Gynecologic Oncology.
150:391-397.
2018
|
|
| 2018
|
A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer
2018
|
|
| 2018
|
High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women with Low-Grade Cervical Cytology.
Journal of Lower Genital Tract Disease.
22:207-211.
2018
|
|
| 2018
|
Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
Gynecologic Oncology.
149:337-340.
2018
|
|
| 2018
|
Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma.
Molecular Cancer Research.
16:813-824.
2018
|
|
| 2018
|
Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?.
Gynecologic Oncology.
149:49-52.
2018
|
|
| 2018
|
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma.
Cancer Medicine.
7:616-625.
2018
|
|
| 2018
|
Feasibility of complete salpingectomy compared with standard postpartum tubal ligation at cesarean delivery a randomized controlled trial.
Obstetrics and Gynecology.
132:20-27.
2018
|
|
| 2017
|
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
Gynecologic Oncology.
147:98-103.
2017
|
|
| 2017
|
The evolution of and evidence for opportunistic salpingectomy.
Obstetrics and Gynecology.
130:814-824.
2017
|
|
| 2017
|
Malignant Brenner tumor associated with a germline BRCA2 mutation.
Gynecologic Oncology Reports.
21:17-19.
2017
|
|
| 2017
|
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic Oncology.
145:291-297.
2017
|
|
| 2017
|
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort.
Gynecologic Oncology.
144:274-278.
2017
|
|
| 2017
|
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?.
Gynecologic Oncology.
144:125-129.
2017
|
|
| 2017
|
Does obesity affect pathologic agreement of initial and final tumor grade of disease in endometrial cancer patients?.
International Journal of Gynecological Cancer.
27:714-719.
2017
|
|
| 2016
|
Drawing the Line in Risk-Reducing Gynecologic Surgery in Women with a BRCA Mutation.
JAMA Oncology.
2:1409-1411.
2016
|
|
| 2016
|
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Gynecologic Oncology.
142:25-29.
2016
|
|
| 2016
|
See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology?.
Journal of Lower Genital Tract Disease.
20:243-246.
2016
|
|
| 2016
|
Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?.
Gynecologic Oncology.
143:617-621.
2016
|
|
| 2016
|
Staging Lymphadenectomy in Patients with Clear Cell Carcinoma of the Ovary.
International Journal of Gynecological Cancer.
26:120-124.
2016
|
|
| 2015
|
The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions..
Current Obstetrics and Gynecology Reports.
4:234-239.
2015
|
|
| 2015
|
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.
Gynecologic Oncology.
139:59-62.
2015
|
|
| 2015
|
Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian cancers: An observational study ancillary analysis.
Gynecologic Oncology.
138:267-271.
2015
|
|
| 2015
|
Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project.
International Journal of Gynecological Cancer.
25:798-801.
2015
|
|
| 2015
|
Laparoscopic staging of ovarian immature teratomas: A report on three cases
2015
|
|
| 2015
|
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?.
Gynecologic Oncology.
136:43-47.
2015
|
|
| 2014
|
Diabetes mellitus and ovarian cancer: More complex than just increasing risk.
Gynecologic Oncology.
135:273-277.
2014
|
|
| 2014
|
Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer.
International Journal of Gynecological Cancer.
24:1480-1485.
2014
|
|
| 2014
|
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
American Journal of Obstetrics and Gynecology.
211:68.e1-68.e8.
2014
|
|
| 2014
|
Black race independently predicts worse survival in uterine carcinosarcoma.
Gynecologic Oncology.
133:238-241.
2014
|
|
| 2014
|
Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
2014
|
|
| 2014
|
Primary invasive breast carcinoma arising in mammary-like glands of the vulva managed with excision and sentinel lymph node biopsy.
Gynecologic Oncology Reports.
7:7-9.
2014
|
|
| 2014
|
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma.
Gynecologic Oncology.
133:234-237.
2014
|
|
| 2014
|
Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.
Gynecologic Oncology.
133:142-146.
2014
|
|
| 2013
|
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Cancer.
119:3653-3661.
2013
|
|
| 2013
|
In reply.
Obstetrics and Gynecology.
122:906-907.
2013
|
|
| 2013
|
Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?.
Gynecologic Oncology.
130:317-322.
2013
|
|
| 2013
|
Growing teratoma syndrome: Brief communication and algorithm for management.
Australian and New Zealand Journal of Obstetrics and Gynaecology.
53:318-321.
2013
|
|
| 2013
|
Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials.
Gynecologic Oncology.
129:251-257.
2013
|
|
| 2013
|
Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women
2013
|
|
| 2013
|
Malignant pericardial effusion and pericardial tumor involvement secondary to cervical cancer
2013
|
|
| 2013
|
Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.
Gynecologic Oncology.
131:158-162.
2013
|
|
| 2013
|
Trends in hospital volume and patterns of referral for women with gynecologic cancers: Adherence to treatment guidelines for ovarian cancer as a measure of quality care.
Obstetrics and Gynecology.
122:905-906.
2013
|
|
| 2012
|
Re: "The utilization of palliative care in gynecologic oncology patients near the end of life"..
Gynecologic Oncology.
127:678-679.
2012
|
|
| 2012
|
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.
Gynecologic Oncology.
127:267-272.
2012
|
|
| 2012
|
Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy.
Gynecologic Oncology.
126:69-72.
2012
|
|
| 2012
|
Robotic surgery applications in the management of gynecologic malignancies
2012
|
|
| 2012
|
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Journal of Clinical Oncology.
30:362-371.
2012
|
|
| 2012
|
Peripartum cardiomyopathy and acute fatty liver of pregnancy: One patient with two Zebras
2012
|
|
| 2011
|
Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot study.
Gynecologic Oncology.
123:360-364.
2011
|
|
| 2011
|
Erratum: Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions (Gynecologic Oncology (2010) 118 (274-277)).
Gynecologic Oncology.
121:643.
2011
|
|
| 2011
|
Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation.
Gynecologic Oncology.
121:637-638.
2011
|
|
| 2011
|
Reaction to a surgical implant foreign body masquerading as recurrent uterine sarcoma.
Obstetrics and Gynecology.
117:450-452.
2011
|
|
| 2011
|
Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.
Gynecologic Oncology.
122:501-504.
2011
|
|
| 2011
|
Surgically managed stage i endometrial cancer in a low-volume center: Outcomes and complications in a military residency program.
American Journal of Obstetrics and Gynecology.
205:356.e1-356.e5.
2011
|
|
| 2010
|
Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions.
Gynecologic Oncology.
118:274-277.
2010
|
|
| 2010
|
Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancy.
Gynecologic Oncology.
117:387-388.
2010
|
|
| 2010
|
Undifferentiated uterine sarcoma presenting as a pathologic humerus fracture
2010
|
|
| 2009
|
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: A report of 2 cases
2009
|
|
| 2009
|
Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapy.
International Journal of Gynecological Cancer.
19:888-891.
2009
|
|
| 2009
|
Cervical signet-ring cell carcinoma presenting as a synchronous primary carcinoma with uterine adenocarcinoma
2009
|
|
| 2009
|
Hot and blue. Lymphoscintigraphy might be useful in cervical cancer surgery.
American Journal of Obstetrics and Gynecology.
201:223.e1-223.e2.
2009
|
|
| 2008
|
Conservative Management of Postoperative Fever in Gynecologic Patients Undergoing Major Abdominal or Vaginal Operations.
Journal of the American College of Surgeons.
207:393-397.
2008
|
|
| 2008
|
Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer.
Gynecologic Oncology.
110:268-269.
2008
|
|
| 2007
|
Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
Gynecologic Oncology.
107:398-403.
2007
|
|
| 2007
|
Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: A retrospective university experience.
International Journal of Gynecological Cancer.
17:998-1002.
2007
|
|
| 2007
|
A multi-institutional review of outcomes of endometrial stromal sarcoma.
Gynecologic Oncology.
105:630-634.
2007
|
|
| 2007
|
Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging.
International Journal of Gynecological Cancer.
17:731-734.
2007
|
|
| 2007
|
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
Gynecologic Oncology.
104:591-595.
2007
|
|
| 2006
|
Surgical staging in endometrial cancer.
Oncology (Williston Park, N.Y.).
20:45-50.
2006
|
|
| 2006
|
Bowel Resection at the Time of Primary Debulking for Epithelial Ovarian Carcinoma: Outcomes in Patients Treated with Platinum and Taxane-Based Chemotherapy.
Journal of the American College of Surgeons.
203:527-532.
2006
|
|
| 2006
|
Inflammatory pseudotumor of pelvic lymph nodes.
Obstetrics and Gynecology.
108:779-782.
2006
|
|
| 2006
|
Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: A university teaching hospital experience.
International Journal of Gynecological Cancer.
16:1766-1769.
2006
|
|
| 2006
|
Synchronous primary endometrial and ovarian carcinoma in a patient with marantic endocarditis.
Obstetrics and Gynecology.
108:748-750.
2006
|
|
| 2006
|
Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.
Gynecologic Oncology.
102:338-342.
2006
|
|
| 2006
|
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients
2006
|
|
| 2006
|
Current controversies in the biology and management of ovarian tumors of low malignant potential.
Women's Oncology Review.
6:15-25.
2006
|
|
| 2006
|
Erratum: Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter (Gene Therapy (2004) vol. 11 (645-648) 10.1038/sj.gt.3302089)
2006
|
|
| 2006
|
Use of a fascial prosthesis for management of abdominal compartment syndrome secondary to obstetric hemorrhage.
Obstetrics and Gynecology.
107:493-496.
2006
|
|
| 2005
|
Predictors of outcomes for women with cervical carcinoma.
Gynecologic Oncology.
99:432-436.
2005
|
|
| 2005
|
A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia.
Obstetrical and Gynecological Survey.
60:96-97.
2005
|
|
| 2005
|
A prospective evaluation of "see and treat" in women with HSIL Pap smear results: Is this an appropriate strategy?.
Journal of Lower Genital Tract Disease.
9:2-6.
2005
|
|
| 2005
|
Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis.
Gynecologic Oncology.
97:387-394.
2005
|
|
| 2005
|
Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy.
Gynecologic Oncology.
97:713-715.
2005
|
|
| 2005
|
Validation of referral guidelines for women with pelvic masses.
Obstetrics and Gynecology.
105:35-41.
2005
|
|
| 2004
|
Protrusio acetabuli presenting as a complex pelvic mass after total hip arthroplasty.
Obstetrics and Gynecology.
104:1187-1189.
2004
|
|
| 2004
|
A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia.
Journal of Lower Genital Tract Disease.
8:280-284.
2004
|
|
| 2004
|
The impact of aborted radical hysterectomy in patients with cervical carcinoma.
Gynecologic Oncology.
95:204-207.
2004
|
|
| 2004
|
Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma.
Gynecologic Oncology.
94:352-362.
2004
|
|
| 2004
|
Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients..
Journal of Clinical Oncology.
22:5044.
2004
|
|
| 2004
|
Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy
2004
|
|
| 2004
|
Transcriptional Blocks Limit Adenoviral Replication in Primary Ovarian Tumor.
Clinical Cancer Research.
10:3189-3194.
2004
|
|
| 2004
|
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
Cancer Gene Therapy.
11:256-262.
2004
|
|
| 2004
|
Immunohistochemical Evaluation of the c-kit Proto-oncogene in Sarcomas of the Uterus: A Case Series
2004
|
|
| 2004
|
Knowledge, Beliefs, and Practices Concerning Seat Belt Use during Pregnancy.
Journal of Trauma and Acute Care Surgery.
56:670-675.
2004
|
|
| 2004
|
Primary lung large cell carcinoma metastatic to the vulva: A case report and review of the literature.
Gynecologic Oncology.
94:829-831.
2004
|
|
| 2004
|
Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.
Gynecologic Oncology.
93:429-434.
2004
|
|
| 2004
|
Single-chain antibodies: A therapeutic modality for cancer gene therapy (review)..
International Journal of Oncology.
24:765-771.
2004
|
|
| 2004
|
The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy.
Gynecologic Oncology.
92:215-219.
2004
|
|
| 2004
|
Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter
2004
|
|
| 2003
|
Primary extrarenal rhabdoid tumor of the ovary: A case report
2003
|
|
| 2003
|
Complications of indwelling venous access devices in patients with gynecologic malignancies.
Gynecologic Oncology.
91:591-595.
2003
|
|
| 2003
|
Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.
Gynecologic Oncology.
91:470-475.
2003
|
|
| 2002
|
A guest editorial: Stump the professor.
Obstetrical and Gynecological Survey.
57:785-787.
2002
|
|
| 2002
|
Uterine leiomyosarcoma metastatic to the thyroid.
Obstetrics and Gynecology.
100:1122-1124.
2002
|
|
| 2002
|
Uterine leiomyosarcoma metastatic to the thyroid..
Obstetrics and Gynecology.
100:1122-1124.
2002
|
|
| 2002
|
A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis.
Gynecologic Oncology.
87:57-63.
2002
|
|
| 2002
|
Conservative management of Stage I endometrial carcinoma after surgical staging.
Gynecologic Oncology.
84:194-200.
2002
|
|
| 1991
|
Team-managed care for older adults. A clinical demonstration of a community model..
Journal of Gerontological Nursing.
17:25-28.
1991
|
|
